WallachBeth Capital Announces Purchase and Sale of LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT)

Rhea-AI Summary

LIXTE Biotechnology Holdings has entered into definitive agreements for a registered direct offering of 2,900,000 shares at $2.00 per share, expecting gross proceeds of approximately $5.8 million. The offering's closing is anticipated around April 14, 2022, pending customary conditions. This move is supported by a shelf registration statement filed with the SEC. LIXTE is focused on developing innovative cancer therapies, highlighting its lead compound LB-100, which has shown promising results in early trials.

Positive

• Gross proceeds of approximately $5.8 million to support operations.
• Lead compound LB-100 shows potential in cancer treatment with promising early trial results.

Negative

• None.

$5.8 Million Registered Direct Offering Priced At-The-Market

JERSEY CITY, N.J., April 13, 2022  /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced that LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, has entered into definitive agreements for the purchase and sale of 2,900,000 shares of LIXTE's common stock at a purchase price of $2.00 per share in a registered direct offering.  The gross proceeds to LIXTE from this offering are expected to be approximately $5.8 million before deducting the placement agents' fees and other offering expenses.

WallachBeth Capital, LLC and WestPark Capital, Inc. are acting as co-placement agents for the offering.  The closing of the offering is expected to occur on or about April 14, 2022, subject to the satisfaction of customary closing conditions.

The shares of common stock are being offered by Lixte pursuant to a "shelf" registration statement on Form S-3 (File No. 333-252430) previously filed with the Securities and Exchange Commission (the "SEC") on January 26, 2021 and declared effective by the SEC on February 5, 2021. The offering of the securities will be made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A final prospectus supplement and accompanying prospectus relating to the securities being offered will be filed with the SEC. Electronic copies of the final prospectus supplement and accompanying prospectus may be obtained, when available, on the SEC's website at http://www.sec.gov.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About LIXTE Biotechnology Holdings, Inc.
LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commercializing cancer therapies. Major drivers of cancer are defects in the switches that turn the biochemical pathways in cells on or off. Most cancer research over the past 30 years has focused on the "on" switches because the "off" switches, especially the master "off" switch protein phosphatase (PP2A), were believed to cause intolerable toxicity in patients. LIXTE has achieved a breakthrough with its novel, first-in-class lead clinical compound and PP2A inhibitor, LB-100, demonstrating that LB-100 is readily tolerated in cancer patients at doses associated with anti-cancer activity. Based on extensive published preclinical data (see www.lixte.com), LB-100 has the potential to significantly improve outcomes for patients undergoing various chemotherapies or immunotherapies. LIXTE's new approach has no known competitors and is covered by a comprehensive patent portfolio. Initial proof-of-concept clinical trials are in progress.

About WallachBeth Capital LLC
WallachBeth Capital offers a robust range of capital markets and investment banking services to the healthcare community, connecting corporate clients with leading institutions, creating value for both issuers and investors. The firm's experience includes initial public offerings, follow-on issues, PIPE offerings, and private transactions. WallachBeth Capital is a leading provider of institutional execution services, offering clients a full spectrum of solutions to help them navigate increasingly complex markets. The firm's website is located at www.wallachbeth.com.

Related Links
https://www.wallachbeth.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/wallachbeth-capital-announces-purchase-and-sale-of-lixte-biotechnology-holdings-inc-nasdaq-lixt-301524782.html

SOURCE WallachBeth Capital LLC

FAQ

What is the significance of the $5.8 million registered direct offering by LIXTE?

The offering will provide $5.8 million in gross proceeds to help fund LIXTE's operations and drug development efforts.

When is the closing date for LIXTE's direct offering?

The closing of the offering is expected to occur on or about April 14, 2022.

What is the purchase price per share for LIXTE's stock in the recent offering?

The purchase price per share for the recent offering is $2.00.

What is LB-100 and why is it important for LIXTE?

LB-100 is LIXTE's lead clinical compound; it is a PP2A inhibitor showing potential for improved cancer treatment outcomes.

How many shares are being offered in LIXTE's recent stock offering?

LIXTE is offering 2,900,000 shares in the recent registered direct offering.